• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

TELIK, INC.

NASDAQ:TELK

$5.23 -$0.39 (-6.94%)

REAL-TIME: Last trade at

Jump to this page for:

Related Resources

Telik rises 22.4%

5/24/2012 by Theflyonthewall.com

BreakoutStocks.com Reports 3 Companies Advancing In Today's Market - Rosetta Genomics Ltd, Mgt Capital Investments Inc, Telik

5/16/2012 by PRWeb

Telik rises 26.2%

5/16/2012 by Theflyonthewall.com

Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra i

5/15/2012 by StockWatch

Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome

5/15/2012 by PR Newswire

Telik Announces First Quarter 2012 Financial Results

5/9/2012 by PR Newswire

Telik Regains Compliance With Minimum Bid Price Requirement

4/17/2012 by PR Newswire

Telik falls 21.6%

4/13/2012 by Theflyonthewall.com

Telik falls 21.2%

4/13/2012 by Theflyonthewall.com

Wall Street Analyst Forum to host a conference

4/10/2012 by Theflyonthewall.com

Telik falls 21.7%

4/2/2012 by Theflyonthewall.com

Telik falls 14.3%

4/2/2012 by Theflyonthewall.com

Telik falls 27.1%

4/2/2012 by Theflyonthewall.com

Telik Announces Reverse Split of Common Stock

3/30/2012 by StockWatch

Telik announces 1-for-30 reverse split of common stock

3/30/2012 by Theflyonthewall.com

Telik Announces Reverse Split of Common Stock

3/30/2012 by PR Newswire

Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance

2/23/2012 by Genetic Engineering News

Telik, Inc. (TELK) Reports Q4 Loss of $0.05, Offers FY12 Outlook

2/23/2012 by StreetInsider.com

Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance

2/23/2012 by PR Newswire

Telik expands Phase 2 Trial of Telcyta in Hematologic Malignancies

2/21/2012 by Theflyonthewall.com

Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference

2/8/2012 by PR Newswire

Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference

1/4/2012 by PR Newswire

Telik Announces Phase 1 Results Of A Multicenter Study Of Telintra® (Ezatiostat Hydrochloride, TLK199) In Combination With Revlimid® (Lenalidomide) In Patients With Myelodysplastic Syndrome

12/15/2011 by Biocompare

Telik announces data from Phase 1 study of telintra in combination with revlimid

12/13/2011 by Theflyonthewall.com

Telik Announces Phase 1 Results of a Multicenter Study of Telintra® (Ezatiostat Hydrochloride, TLK199) in Combination with Revlimid® (Lenalidomide) in Patients with Myelodysplastic Syndrome

12/13/2011 by PR Newswire

Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology

11/10/2011 by PR Newswire

Telik Announces Third Quarter 2011 Financial Results

11/3/2011 by PR Newswire

Telik's Tenindra for neutropenia shows positive results in patient

11/3/2011 by Theflyonthewall.com

Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®

11/3/2011 by PR Newswire

Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

11/1/2011 by PR Newswire

Telik begins Phase 2b trial of Telintra for myelodysplastic syndrome

10/13/2011 by Theflyonthewall.com

Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome

10/13/2011 by PR Newswire

Telik Announces Publication In The Journal Cancer Of A Phase 2 Randomized Multicenter Study Of Two Extended Dosing Schedules Of Oral Ezatiostat In Low To Intermediate-1 Risk Myelodysplastic Syndrome

9/29/2011 by Biocompare

Telik reports Q2 EPS (6c) vs. consensus (7c)

8/11/2011 by Theflyonthewall.com

Telik Announces Second Quarter 2011 Financial Results

8/11/2011 by PR Newswire

Telik (TELK) Files $25M Mixed Shelf

8/8/2011 by StreetInsider.com

Telik files $25M mixed securities shelf

8/8/2011 by Theflyonthewall.com

Telik Announces Initiation Of A Phase 2 Clinical Trial Of Telintra® (Ezatiostat HCl) In Patients With Revlimid® Refractory Or Resistant Deletion 5q Myelodysplastic Syndrome

6/9/2011 by Biocompare

Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra (Ezatiostat HCl) in Patients With Revlimid Refractory or Resistant Deletion 5q Myelodysplastic Syndrome

6/7/2011 by Genetic Engineering News

Telik initiates Phase 2 clinical trial for oral Telintra

6/7/2011 by Theflyonthewall.com
See More Articles...